# A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

> **NCT06113744** · PHASE1 · UNKNOWN · sponsor: **CNBG-Virogin Biotech (Shanghai) Ltd.** · enrollment: 164 (estimated)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** COVID-19 Vaccine (Vero Cell) ,Inactivated
- **BIOLOGICAL:** COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg
- **BIOLOGICAL:** COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg
- **BIOLOGICAL:** COVID-19 mRNA Vaccine (ZSVG-02-O) 60 μg

## Key facts

- **NCT ID:** NCT06113744
- **Lead sponsor:** CNBG-Virogin Biotech (Shanghai) Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-10
- **Primary completion:** 2023-06-30
- **Final completion:** 2024-06
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2023-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06113744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06113744, "A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06113744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*